PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
A phase I clinical trial evaluated the safety of M. glomerata oral solution in healthy volunteers over two weeks of use [PMID:37562463]
Used as a natural bronchodilator, expectorant, and cough suppressant for upper respiratory problems [PMID:20636868]
Ent-kaurenoic acid-rich extracts showed antibacterial activity against bacteria responsible for dental caries and endodontic infections [PMID:28627377, PMID:27316976]
An ethanolic extract fraction (MG1) significantly reduced plasma exudation and neutrophil/eosinophil infiltration in ovalbumin-induced allergic pleurisy [PMID:10432203]
Complexes of ent-kaurenoic acid with beta-cyclodextrin demonstrated antitumor activity in a mouse model [PMID:36529360]
Safety & adverse effects
Pregnancy & lactation
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 40283987 (2025) — Biological Activities of Mikania glomerata and Mikania laevigata: A Scoping Review and Evidence Gap Mapping. · Pharmaceuticals (Basel, Switzerland)
- 2.PMID: 20636868 (2010) — Scientific evidence for Mikania laevigata and Mikania glomerata as a pharmacological tool. · The Journal of pharmacy and pharmacology
- 3.PMID: 11261581 (2001) — Germacranolides from Mikania guaco. · Phytochemistry
- 4.PMID: 22932215 (2012) — Preparation of dry extract of Mikania glomerata Sprengel (Guaco) and determination of its coumarin levels by spectrophotometry and HPLC-UV. · Molecules (Basel, Switzerland)
- 5.PMID: 16755468 (2006) — LC characterisation of guaco medicinal extracts, Mikania laevigata and M. glomerata, and their effects on allergic pneumonitis.